Simrat Randhawa sold $7.4M of DNTH
EVP, Head of R&D at Dianthus Therapeutics, Inc. /DE/. 196,538 shares at an average of $37.55, traded Nov 13, 2025, filed Nov 14, 2025.
Score components
- +15RoleOfficer
- +25Trade size$7.4M at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +3.1%, 3m +16.0%, 6m +110.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001992260-25-000008, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 13, 2025 | MOption exercise Common Stock10b5-1 | +83,978 | $8.44 | $709k | 87,978 | Nov 14, 2025 |
| Nov 13, 2025 | MOption exercise Common Stock10b5-1 | +3,529 | $17.88 | $63k | 91,507 | Nov 14, 2025 |
| Nov 13, 2025 | SOpen-market sale Common Stock10b5-1 | -26,166 | $35.80 | $937k | 65,341 | Nov 14, 2025 |
| Nov 13, 2025 | SOpen-market sale Common Stock10b5-1 | -42,765 | $37.04 | $1.6M | 22,576 | Nov 14, 2025 |
| Nov 13, 2025 | SOpen-market sale Common Stock10b5-1 | -18,576 | $37.72 | $701k | 4,000 | Nov 14, 2025 |
| Nov 14, 2025 | MOption exercise Common Stock10b5-1 | +40,287 | $17.88 | $720k | 44,287 | Nov 14, 2025 |
| Nov 14, 2025 | MOption exercise Common Stock10b5-1 | +37,494 | $21.77 | $816k | 81,781 | Nov 14, 2025 |
| Nov 14, 2025 | MOption exercise Common Stock10b5-1 | +31,250 | $22.07 | $690k | 113,031 | Nov 14, 2025 |
| Nov 14, 2025 | SOpen-market sale Common Stock10b5-1 | -109,031 | $38.14 | $4.2M | 4,000 | Nov 14, 2025 |
| Nov 13, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -83,978 | $0.00 | $0 | 11,996 | Nov 14, 2025 |
| Nov 13, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,529 | $0.00 | $0 | 116,471 | Nov 14, 2025 |
| Nov 14, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -40,287 | $0.00 | $0 | 76,184 | Nov 14, 2025 |
| Nov 14, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -37,494 | $0.00 | $0 | 62,506 | Nov 14, 2025 |
| Nov 14, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -31,250 | $0.00 | $0 | 118,750 | Nov 14, 2025 |
Related signals
Other insiders at Dianthus Therapeutics, Inc. /DE/ and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | Dianthus Therapeutics, Inc. /DE/ | Edward Carr CHIEF ACCOUNTING OFFICER | $2.0M 20,000 shares | -100% | |
| 33Weak | Dianthus Therapeutics, Inc. /DE/ | Simrat Randhawa EVP, Head of R&D | $2.5M 23,124 shares | -85% | |
| 30Weak | Dianthus Therapeutics, Inc. /DE/ | Simon Read director | $327k 2,778 shares | -100% | |
| 29Weak | Dianthus Therapeutics, Inc. /DE/ | Simon Read director | $304k 2,777 shares | -100% | |
| 40Moderate | Dianthus Therapeutics, Inc. /DE/ | Adam M Veness SVP, General Counsel and Sec. | $2.2M 20,000 shares | -522% | |
| 38Weak | Dianthus Therapeutics, Inc. /DE/ | Anne McGeorge director | $845k 7,750 shares | -100% | |
| 50Moderate | Dianthus Therapeutics, Inc. /DE/ | Marino Garcia CEO AND PRESIDENT | $18M 166,000 shares | -72% | |
| 32Weak | Dianthus Therapeutics, Inc. /DE/ | Ryan Savitz EVP, CFO & CBO | $3.2M 31,249 shares | -100% | |
| 25Weak | Dianthus Therapeutics, Inc. /DE/ | Adam M Veness SVP, General Counsel and Sec. | $2.4M 30,000 shares | -100% | |
| 25Weak | Dianthus Therapeutics, Inc. /DE/ | Simrat Randhawa EVP, Head of R&D | $2.4M 26,530 shares | -87% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.